Journal
MOLECULAR AND CELLULAR ENDOCRINOLOGY
Volume 248, Issue 1-2, Pages 61-71Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.mce.2005.12.007
Keywords
hydroxysteroid dehydrogenase; steroid metabolism; 17 beta-hydroxysteroid dehydrogenase; pre-receptor control; short-chain dehydrogenase/reductase
Categories
Funding
- Wellcome Trust Funding Source: Medline
Ask authors/readers for more resources
17 beta-Hydroxysteroid dehydrogenases (17 beta-HSDs) catalyze the NAD(P)(H) dependent oxidoreduction at C17 oxo/beta-hydroxyl groups of androgen and estrogen hormones. This reversible reaction constitutes an important pre-receptor control mechanism for nuclear receptor ligands, since the conversion switches between the 17 beta-OH receptor ligands and their inactive 17-oxo metabolites. At present, 14 mammalian 17 beta-HSDs are described, of which at least 11 exist within the human genome, encoded by different genes. The enzymes differ in their expression pattern, nucleotide cofactor preference, steroid substrate specificity and subcellular localization, and thus constitute a complex system ensuring cell-specific adaptation and regulation of sex steroid hormone levels. Broad and overlapping substrate specificities with enzymes involved in lipid metabolism suggest interactions of several 17 beta-HSDs with other metabolic pathways. Several 17 beta-HSDs enzymes constitute promising drug targets, of particular importance in cancer, metabolic diseases, neurodegeneration and possibly immunity. (c) 2005 Elsevier Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available